[1]
Baranano DE,Rao M,Ferris CD,Snyder SH, Biliverdin reductase: a major physiologic cytoprotectant. Proceedings of the National Academy of Sciences of the United States of America. 2002 Dec 10; [PubMed PMID: 12456881]
[2]
Wu B,Wu Y,Tang W, Heme Catabolic Pathway in Inflammation and Immune Disorders. Frontiers in pharmacology. 2019; [PubMed PMID: 31396090]
[4]
Wegiel B,Otterbein LE, Go green: the anti-inflammatory effects of biliverdin reductase. Frontiers in pharmacology. 2012; [PubMed PMID: 22438844]
[5]
Ollinger R,Yamashita K,Bilban M,Erat A,Kogler P,Thomas M,Csizmadia E,Usheva A,Margreiter R,Bach FH, Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell cycle (Georgetown, Tex.). 2007 Jan 1; [PubMed PMID: 17245120]
[6]
Nakao A,Murase N,Ho C,Toyokawa H,Billiar TR,Kanno S, Biliverdin administration prevents the formation of intimal hyperplasia induced by vascular injury. Circulation. 2005 Jul 26; [PubMed PMID: 16027253]
[7]
Bisht K,Tampe J,Shing C,Bakrania B,Winearls J,Fraser J,Wagner KH,Bulmer AC, Endogenous Tetrapyrroles Influence Leukocyte Responses to Lipopolysaccharide in Human Blood: Pre-Clinical Evidence Demonstrating the Anti-Inflammatory Potential of Biliverdin. Journal of clinical [PubMed PMID: 25177524]
[8]
Wegiel B,Gallo D,Csizmadia E,Roger T,Kaczmarek E,Harris C,Zuckerbraun BS,Otterbein LE, Biliverdin inhibits Toll-like receptor-4 (TLR4) expression through nitric oxide-dependent nuclear translocation of biliverdin reductase. Proceedings of the National Academy of Sciences of the United States of America. 2011 Nov 15; [PubMed PMID: 22042868]
[9]
Bisht K,Wegiel B,Tampe J,Neubauer O,Wagner KH,Otterbein LE,Bulmer AC, Biliverdin modulates the expression of C5aR in response to endotoxin in part via mTOR signaling. Biochemical and biophysical research communications. 2014 Jun 20; [PubMed PMID: 24814708]
[10]
Takei R,Inoue T,Sonoda N,Kohjima M,Okamoto M,Sakamoto R,Inoguchi T,Ogawa Y, Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PloS one. 2019; [PubMed PMID: 31577826]
[11]
Adin CA,VanGundy ZC,Papenfuss TL,Xu F,Ghanem M,Lakey J,Hadley GA, Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response. Cell transplantation. 2017 Jan 24; [PubMed PMID: 27393133]
[13]
Memon N,Weinberger BI,Hegyi T,Aleksunes LM, Inherited disorders of bilirubin clearance. Pediatric research. 2016 Mar; [PubMed PMID: 26595536]
[14]
Ayer A,Zarjou A,Agarwal A,Stocker R, Heme Oxygenases in Cardiovascular Health and Disease. Physiological reviews. 2016 Oct; [PubMed PMID: 27604527]
[15]
Chhem-Kieth S,Skou PB,Lametsch R,Hansen ET,Ruiz-Carrascal J, Investigation of nitrite alternatives for the color stabilization of heme-iron hydrolysates. Journal of food science and technology. 2018 Oct; [PubMed PMID: 30228427]